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Background: Hepatic steatosis is often seen in patients with chronic hepatitis C (CH-C). It is still unclear whether
these patients have an impaired mitochondrial β-oxidation. In this study we assessed mitochondrial β-oxidation in
CH-C patients by investigating ketogenesis during fasting.
Methods: This study consisted of thirty patients with CH-C. Serum levels of insulin and hepatitis C virus (HCV) core
protein were measured by chemiluminescence enzyme immunoassay. The subjects were then fasted, and venous
blood samples were drawn 12 h and 15 h after the start of fasting. The levels of blood ketone bodies were
measured by an enzymatic cycling method. The rate of change in total ketone body concentration was compared
with that in eight healthy volunteers.
Results: The rate of change in total ketone body concentration between 12 h and 15 h after the start of fasting was
significantly lower in CH-C patients than in healthy volunteers (129.9% (8.5-577.3%) vs. 321.6% (139.6-405.4%); P <0.01).
The rate of change in total ketone body concentration in patients with a serum level of HCV core protein of 10000
fmol/L or higher was significantly lower than in patients with a level of less than 10000 fmol/L (54.8% (8.5-304.3%) vs.
153.6% (17.1-577.3%); P <0.05). The rate of change in total ketone body concentration in patients with a homeostasis
model assessment of insulin resistance (HOMA-IR) of 2.5 or higher was significantly lower than in patients with a
HOMA-IR of less than 2.5 (56.7% (8.5-186.7%) vs. 156.4% (33.3-577.3%); P <0.01).
Conclusions: These results suggest that mitochondrial β-oxidation is impaired, possibly due to HCV infection in
patients with CH-C.
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Hepatitis C virus (HCV) infection is a major cause of
chronic liver injury. Hepatic steatosis is one of histologic
features of chronic HCV infection with a risk of progres-
sion of liver diseases [1]. Hepatic steatosis is caused by
some mechanisms, which include an increase of fatty acids
uptake and synthesis, a decrease of fatty acids β-oxidation,
or low level of secretion of very-low density lipoprotein.
HCV core protein-transgenic mice develop hepatic steatosis
due to impaired β-oxidation caused by mitochondrial* Correspondence: s.chikako@med.id.yamagata-u.ac.jp
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reproduction in any medium, provided the ordamage [2]. However, there has been no evidence of im-
paired β-oxidation in patients with chronic hepatitis C
(CH-C) in vivo.
During starvation, mitochondria produces acetyl CoA,
which is converted into ketone bodies by fatty acids
β-oxidation. In patients with impaired hepatic mitochon-
drial β-oxidation, ketogenesis is expected to be inadequate.
Adult-onset type 2 citrullinemia (CTLN2) has been dem-
onstrated to present as non-alcoholic fatty liver disease
(NAFLD) [3]. CTLN 2 is associated with mutations in the
SLC25A13 gene encoding citrin, which is a component of
the mitochondrial malate-aspartate shuttle. Functional de-
fectiveness of citrin impairs not only transport of aspartate
from mitochondria but that of NADH into mitochondria.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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compensatory production of acetyl CoA, which in turn
stimulates fatty acid synthesis. In addition, mitochondrial
accumulation of malonyl CoA in a high NADH/NAD+ en-
vironment suppresses fatty acid oxidation. These circum-
stances lead to hepatic steatosis in patients with CTLN 2
[4]. Inui et al. have demonstrated that suppression of fatty
acid oxidation is accompanied by impaired ketogenesis in
such patients [5].
Based on this background, we measured the concen-
tration of blood ketone bodies during fasting in order to
evaluate mitochondrial β-oxidation in patients with CH-
C, and thus to investigate a mechanism of steatosis asso-
ciated with HCV infection. Here, we report for the first




Thirty patients (14 male and 16 female, the mean age 54.2,
ranging from 22 to 74 years old) with CH-C were studied.
The patients were admitted to Yamagata University Hos-
pital for treatment between March 2006 and May 2009. All
of the patients had been positive for both serum anti-HCV
and HCV RNA for more than 6 months, and had elevated
levels of serum alanine aminotransferase (ALT). They were
all negative for hepatocellular carcinoma, hepatitis B, auto-
immune hepatitis, primary biliary cirrhosis, heart failure,
renal insufficiency, a history of diabetes mellitus, excess al-
cohol intake (daily ethanol consumption >20 g) or drug
abuse. None of the patients fulfilled the criteria for Meta-
bolic Syndrome in Japan [6,7], i.e. the presence of at least
two of the following three abnormalities in addition to vis-
ceral obesity (waist circumference: 85 cm or more in men,
90 cm or more in women): 1) triglycerides ≥150 mg/dl
and/or HDL-cholesterol <40 mg/dl, or receiving treatment
for this type of dyslipidemia; 2) systolic blood pressure
≥130 and/or diastolic blood pressure ≥85, or receiving
treatment for hypertension; 3) fasting glucose ≥110 mg/dl
or receiving treatment for diabetes. As a control group,
eight volunteers (4 male and 4 female) were included (the
mean age 30.5, ranging from 26 to 39 years old). All of
them were healthy, with a BMI of <25 kg/m2, without
medication or severe disease. Written informed consent to
participate was obtained from all subjects, and the study
protocol was approved by The Yamagata University
Hospital Ethics Committee.
Methods
Clinical and laboratory data
Body height, weight and waist circumference were mea-
sured at the time of admission. Body mass index (BMI)
was calculated as: BMI = body weight (kg)/body height
(m)2 . Venous blood samples were collected after a 12-hovernight fast for standard biochemical testing and deter-
mination of serum insulin levels, HCV genotype and HCV
core protein. Serum insulin was determined by chemilumin-
escence enzyme immunoassay (Lumipulseprestoinsulin®,
Fujirebio Inc., Tokyo, Japan). Insulin resistance was deter-
mined based on the homeostasis model assessment of insu-
lin resistance (HOMA-IR). HOMA-IR was calculated using
the formula: [fasting glucose (mg/dl) × fasting insulin (μU/
ml)] / 405 [8]. Insulin resistance was defined as HOMA-IR
>2.5. The amount of HCV core antigen and HCV RNA in
serum were measured by a chemiluminescence enzyme im-
munoassay (Lumispot Eiken HCV antigen®, Eiken Chemical
Co., Ltd., Tokyo, Japan) and an amplicor HCV RNA detec-
tion kit (Amplicor HCV v2.0®, Roche Diagnostics, Tokyo,
Japan) or a real-time PCR assay (COBAS® TaqMan® HCV
Test, Roche Diagnostics, Tokyo, Japan), respectively.
Fasting test
In general, ketone bodies are not detected during periods of
feeding, but after the onset of fasting, glycogen is gradually
consumed and ketone bodies are produced rapidly after
about 12 hours of fasting. The rate of change in ketone
body production between 12 and 15 hours represented the
initial increase, and was interpreted as the initial velocity of
ketogenesis.
Fasting tests were performed in both subjects and volun-
teers. They were permitted to drink water after their last
meal, and blood samples were drawn to measure the pro-
portion of ketone bodies, glucose, insulin, free fatty acid
and triglyceride levels at 12 and 15 h after the last meal.
Carnitine fractionation was also measured at 12 after the
last meal, using an enzymatic cycling method (Total Carni-
tine Kainos®, Free Carnitine Kainos®, Kainos Laboratories,
Inc., Tokyo, Japan). During fasting, urine organic acids were
measured by gas chromatograph-mass spectrometry and
then analyzed using software to determine the presence of
disorders of organic acid metabolism. Serum ketone bod-
ies were measured by an enzymatic cycling method (3-
hydroxybutyrate Kainos®, Total ketone body Kainos®,
ketone body standard reagent 2®, Kainos Laboratories,
Inc. Tokyo, Japan). These measurements were performed
by SRL Inc. (Tokyo, Japan). The rate of change in total ke-
tone body concentration from 12 h to 15 h was calculated
using the equation: (total ketone bodies at 15 h – total ke-
tone bodies at 12 h)/ total ketone bodies at 12 h × 100.
Histological assessment
Liver biopsies were performed under sonographic guidance
in 25 patients who provided informed consent. The liver tis-
sues were fixed in 10% formalin, embedded in paraffin and
stained with hematoxylin-eosin and silver stain. Liver hist-
ology was graded and staged by a pathologist based on the
international classification [9]. The grade of steatosis was
modified as follows: grade 0 = no steatosis and between 0%
Table 1 Patient characteristics
Patients Reference
value
Age (yr) b 54.2 ± 10.6
Male/Female (ratio) 14/16 (0.47)
BMI (kg/m2) b 23.7 ± 2.7 18.5 - 25
ALT (IU/L) a 47.5 (17–167) 8 - 42
γGTP (IU/L) a 41 (13–152) 10 - 47
ChE (IU/L) b 312.9 ± 88.2 185 - 431
Fasting plasma glucose (mg/dL) b 95.5 ± 9.7 70 - 109
Insulin (μIU/mL) a 8.7 (4.5 - 20.4) 1.84 - 12.2
HOMA-IR a 2.0 (1.2 - 5.1)
HOMA-IR > 2.5 (%) 9 (30)
Triglyceride (mg/dL) b 91.4 ± 31.1 30 - 149
Total cholesterol (mg/dL) b 175.2 ± 25.4 129 - 219
Acylcarnitine (μmol/L) a 9.25 (5.7 - 21.1) 6 - 23
HCV RNA (LogIU/mL) b 6.1 ± 0.9




1b / 2a / 2b 20 / 6 / 4
Inflammation A0 / A1 / A2 / A3 0 / 15 / 10 / 0
Fibrosis F0 / F1 / F2 / F3 /
F4
0 / 15 / 7 / 3 / 0
Steatosis G0 / G1 / G2 / G3 6 /18 / 1 / 0
BMI, body mass index; ALT, alanine aminotransferase; γGTP, gamma-
glutamyltranspeptidase; ChE, cholinesterase; HOMA-IR, homeostasis model
assessment of insulin resistance.
Data are amedians (min-max), bthe means ± standard deviation.
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steatosis, grade 1 = between 5% and 33%, grade 2 = between
33% and 66%, and grade 3 =more than 66% according to
the non-alcoholic fatty liver disease Activity Score [10].
Statistical analysis
Results are expressed as the mean ± standard deviation
(SD) or the median and range (in parenthesis). Student’s
t test was used for normally distributed non-paired con-
tinuous variables. The rate of change in total ketone
body concentration was assessed as a parametric value
because the value was distributed parametrically after
logarithmic transformation. Wilcoxon’s signed-ranks test
was used for paired continuous variables. Comparisons
between more than two groups were made by one-way
analysis of variance. All P-values were based on a two-
sided test of statistical significance. Differences at P <0.05
were considered to be statistically significant.
Results
Subject characteristics
The characteristics of thirty patients with chronic hepa-
titis C were shown in Table 1. The mean level of BMI
was less than 25 kg/m2, and that of fasting plasma glu-
cose was within normal range. The mean level of ALT
was greater than the upper limit of normal range. Nine
patients had a status of insulin resistance in whom
HOMA-IR showed a level of 2.5 or greater. All patients
were positive for HCV RNA in whom the mean level of
serum HCV core antigen showed a 6505 fmol/L. Of the
30 patients, 20 (66.7%) were infected with the HCV
genotype 1b, 6 (20.0%) with genotype 2a, and 4 (13.3%)
with genotype 2b. Fifteen (60%) had a liver fibrosis grade
of F1, 7 (28%) had F2, and 3 (12%) had F3. Six (24%) had
a liver steatosis grade of 0, 18 (72%) had grade 1, 1 (4%)
had grade 2, and none had grade 3.
Free fatty acids concentration during fasting in CH-C
patients and healthy volunteers
The concentration of free fatty acids increased by fasting
in CH-C patients and healthy volunteers. The rate of
change in free fatty acids concentration between 12 h
and 15 h was similar in both groups (CH-C patients
48.6% ± 45.0 vs. healthy volunteers 70.3% ± 95.2; ns), as
shown in Figure 1.
Ketone body concentration during fasting in CH-C
patients and healthy volunteers
The levels of total blood ketone bodies were elevated in
both CH-C patients and healthy volunteers 15 h after
the start of fasting, but the rate of change between 12 h
and 15 h after fasting was significantly different between
them. The rate of change in total ketone body concen-
tration between 12 h and 15 h was shown in Figure 2. Itwas significantly lower in CH-C patients than in
healthy volunteers (129.9% (8.5-577.3%) vs. 321.6%
(139.6-405.4%); P <0.01). The rates of change in both
acetoacetate (Figure 3A) and 3-hydroxybutyrate (Figure 3B)
between 12 h and 15 h after fasting were also significantly
lower in CH-C patients than in healthy volunteers
(acetoacetate : 109.5% (−5.8-514.3%) vs. 254.8% (145.5-
341.7%) , 3-hydroxybutyrate : 130.8% (−3.8-606.7%) vs.
337% (135.5-495%) ; P <0.01).
There was a significant positive correlation between
the concentration of total ketone body and the levels
of acylcarnitine (rs 0.56, P <0.01) at 12 h after fasting,
as shown in Figure 4A, similar to the pattern of free
fatty acids (rs 0.54, P <0.01, Figure 4B). The level of
acylcarnitine was significantly lower in CH-C patients
than in healthy volunteers (9.25 μmol/L (5.7-21.1 μmol/L)
vs. 11.65 μmol/L (9.3-17 μmol/L); P <0.05).
Relationship between the rate of change in total ketone
body concentration and clinical parameters in CH-C
patients
We stratified CH-C patients into two groups based on the




























CH-C patients Healthy volunteers
n = 30 n = 8
* *
Figure 2 Total ketone body concentration during fasting in
patients with chronic hepatitis C and healthy volunteers. The
rate of change in total ketone body concentration between 12 h
and 15 h after fasting was significantly lower in patients than in
healthy volunteers (** denotes P <0.01). The line represents a
































CH-C patients Healthy volunteers
n = 30 n = 8
Figure 1 Free fatty acids concentration during fasting in
patients with chronic hepatitis C and healthy volunteers. The
rate of change in free fatty acid concentration between 12 h and 15
h after fasting was similar in both groups. The line represents a
mean value. Welch’s t-test.
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serum HCV core protein level of 10000 fmol/L or
higher was significantly lower than that in patients with
a level of less than 10000 fmol/L (54.8% (8.5-304.3%) vs.
153.6% (17.1-577.3%); P <0.05) (Figure 5). In addition,
the rate of change in total ketone body concentration in
patients with a higher HOMA-IR value (2.5 or greater)
was significantly lower than that in patients with a value
of less than 2.5 (56.7% (8.5-186.7%) vs. 156.4% (33.3-
577.3%); P <0.01) (Figure 6). The patients with biopsy-
proven steatosis had a relatively low rate of change in
total ketone body concentration between 12 h and 15 h
in comparison with those without steatosis, although
the rate was not significantly different between them
(Figure 7). There was no significant difference in the
rate of change in total ketone body concentration among
the HCV genotypes (1b 120.2% (8.5-577.3%), 2a 129.9%
(91.7-304.3%), 2b 135.8% (56.7-253.3%)). No significant
difference in the rate of change in total ketone body con-
centration was demonstrated among the stages of fibrosis
(F1 91.7% (17.1-436%), F2 133% (8.5-283.3%), F3 88.6%
(34.2-577.3%)).Discussion
Hepatitis C virus (HCV) is the leading cause of chronic
hepatitis, subsequent liver cirrhosis and hepatocellular car-
cinoma. Hepatic steatosis is commonly seen in patients
with chronic HCV infection having a high viral load, and it
is in part associated with the development of insulin resist-
ance [1], hepatic fibrosis [11] and hepatocarcinogenesis [12]
during infection. Steatosis is also associated with a lower
rate of sustained response to anti-viral therapy [13], and
shows improvement after successful eradication of HCV by
anti-viral therapy [14].
In general, fat accumulation in hepatocytes can result
from several causes; increase of fatty acid uptake by
hepatocyte, increase of fatty acid synthesis in hepato-
cyte, decrease of hepatic fatty acid oxidation, decrease
of very-low density lipoprotein secretion. The mecha-
nisms of steatosis in HCV infection are not fully
understood. In the previous study using liver biopsy
specimens of patients with HCV infection, it is shown
that expression of peroxisome proliferator-activated
receptor (PPAR)-α is impaired, which is an important
factor in the regulation of mitochondrial β-oxidation

































































































Free fatty acid concentration of 
12h after fasting (mEq/L)
Rs 0.54
P < 0.01
Figure 4 Ketone body concentration are related with acylcarnitine and free fatty acid in patients with chronic hepatitis C. There is a
significant positive correlation between the concentration of total ketone body and the levels of acylcarnitine (rs 0.56, P <0.01),(A), as well as free





























































n = 30 n = 8
* ** *
Figure 3 Ketone body fraction concentration during fasting in patients with chronic hepatitis C and healthy volunteers. The rates of
change in both acetoacetate (A) and 3-hydroxybutyrate (B) between 12 h and 15 h after fasting were significantly lower in patients than in
healthy volunteers (** denotes P <0.01). The line represents a median value. Log transformation was performed. Student’s t test.





























n = 22 n = 8
HCV core protein (fmol/L)
< 10000 10000
*
Figure 5 HCV core protein and the change in total ketone
body concentration during fasting. The rate of change in total
ketone body concentration between 12 h and 15 h after fasting in
patients with a serum HCV core protein level of 10000 fmol/L or
higher was significantly lower than that in patients with a level of
less than 10000 fmol/L (* denotes P <0.05). The line represents a

































Figure 6 Insulin resistance and the change in total ketone body
concentration during fasting. The rate of change in total ketone
body concentration in patients with a higher HOMA-IR value (2.5 or
greater) was significantly lower than that in patients with a value of
less than 2.5 (** denotes P <0.01). The line represents a median
value. Log transformation was performed. Student’s t test.
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served in the state of HCV infection.
However, there is no previous study which investi-
gated whether mitochondrial β-oxidation is impaired
in patients with CH-C in vivo. In the present study,
therefore, we focused on the mechanism of ketogenesis
in humans by investigating ketogenic capacity during
fasting. The rate of change in total ketone body con-
centration between 12 h and 15 h after the start of
fasting was significantly lower in CH-C patients than
in healthy volunteers, while the rate of change in free
fatty acids concentration was similar in both groups.
Therefore there is a possibility that steps from acetyl-
CoA to ketone bodies are impaired in patients with CH-
C. In addition, Hoppel et al. reported that acylcarnitine
increased during fasting and ketone bodies correlated
with short-chain acylcarnitines. It is speculated that the
increase in short-chain acylcarnitines may be a by-
product of fatty acid β-oxidation [16]. In our patients,
the level of acylcarnitine was significantly lower in CH-C
patients than in healthy volunteers. Thus, these support
that mitochondrial β-oxidation is impaired in patients with
CH-C. Further studies are needed to assess which step isinvolved in the impairment of ketone bodies formation in
HCV infection.
During starvation, ketone bodies increase in the body
under conditions of normal mitochondrial β-oxidation.
Since insulin secretion decreases during fasting, synthesis
of triglyceride from acyl CoA is suppressed. Therefore, acyl
CoA is β-oxidized to acetyl CoA in mitochondria. Oxaloac-
etate is used for gluconeogenesis during fasting. Under this
condition, acetyl CoA cannot conjugate oxaloacetate, and
the tricarboxylic acid (TCA) cycle is inhibited. Inhibition of
the TCA cycle also occurs through consumption of nico-
tinamide adenine dinucleotide (NAD+) and the production
of reduced nicotinamide adenine dinucleotide (NADH) via
β-oxidation. Consequently, acetyl CoA shifts towards keto-
genesis. Acetyl CoA enters the TCA cycle and is used as
fuel in muscle. Thus, the liver is the only organ that pro-
duces ketone bodies and secretes them into blood. In indi-
viduals with impaired hepatic mitochondrial β-oxidation, it
is expected that ketogenesis would not be adequate. This is
a reason why measurement of blood ketone body concen-
tration in a fasting state facilitates assessment of mitochon-
drial β-oxidation in vivo [5].
In the present study, the rate of change in total ketone




























n = 6 n = 19
Grade 1, 2Grade 0
Steatosis
NS
Figure 7 Hepatic steatosis and the change in total ketone body
concentration during fasting. The patients with steatosis had a
relatively low rate of change in total ketone body concentration
between 12 h and 15 h after fasting in comparison with those
without steatosis, although it was not significant. The line represents
a median value. Log transformation was performed. Student’s t test.
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cantly lower than in patients with a level of less than
10,000 fmol/L, showing that patients with a higher level
of serum HCV core protein had lower ketogenic capacity.
HCV core protein induces hepatic steatosis with disappear-
ance of the double structure of mitochondrial membranes
in HCV core transgenic mice [2]. HCV core protein is
largely associated with mitochondrial dysfunction [17].
Moreover, recent studies have reported that HCV core
protein downregulates the expression of PPAR-α, which
is abundant in hepatocytes and is an important factor in
the regulation of mitochondrial β-oxidation [15,18].
Our data suggest an impairment of mitochondrial β-
oxidation by HCV infection.
Although no significant relationship between fatty acid
oxidation and the grade of steatosis was demonstrated in
this study (Figure 7), this issue would be worth investi-
gating in a larger cohort of patients. HCV infection in-
duces mitochondrial dysfunction as a result of oxidative
stress, which is closely related to liver inflammation and
hepatocarcinogenesis [19]. Oxidative stress is associated
with impairment of fatty acid oxidation, and thus im-
paired ketogenesis seems to represent the increased
oxidative stress in CH-C patients.Insulin resistance in patients with CH-C has been
reported [20]. At this study, insulin resistance, HOMA-
IR >2.5, was observed in 9 of 30 patients. In this study, a
significant positive correlation was evident between the
concentration of total ketone bodies and that of free
fatty acids. However, in some patients with insulin resist-
ance, the concentrations of both free fatty acids and ke-
tone bodies were not so high. The rate of change in the
concentrations of total ketone bodies was significantly
lower in patients with a higher HOMA-IR value (2.5 or
greater) than in those with a value of less than 2.5. Many
other factors may influence the level of fatty acid. Fur-
ther studies are needed to elucidate the mechanism of
insulin resistance in CH-C patients.
Our CH-C patients were significantly older than the
healthy volunteers. However, we did not observe any sig-
nificant correlation between the age of our subjects and
the rate of change in total ketone body concentration
within the age range investigated (data not shown). Eld-
erly people in good health have a similar capacity to pro-
duce ketones to middle-aged or young adults [21].Conclusions
The results of our study suggest that mitochondrial β-
oxidation is impaired, possibly due to HCV infection. Fur-
ther studies are needed to elucidate the detailed patho-
physiology of impaired fatty acid metabolism in CH-C and
its clinical significance.Abbreviations
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